Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Decitabine and Cedazuridine in Combination with Nivolumab for the Treatment of Unresectable or Metastatic Stage III-IV Mucosal Melanoma

Trial Status: closed to accrual

This phase Ib/II trial tests the safety and side effects of decitabine and cedazuridine (DEC-C) in combination with nivolumab and whether they work in treating patients with stage III-IV mucosal melanoma that cannot be removed by surgery (unresectable) or has spread to other places in the body (metastatic). Decitabine and cedazuridine works by activating the patient's immune system to better recognize tumor cells. Nivolumab is a checkpoint inhibitor drug (anti-PD0-1), which allows the body to recognize tumor cells for destruction. Giving DEC-C and nivolumab may help control the disease in patients with stage III-IV mucosal melanoma.